Day One Biopharmaceuticals lands $130m Series B
Day One Biopharmaceuticals, a provider of targeted therapies for children and adults with cancer, has raised $130 million in Series B financing.
Day One Biopharmaceuticals, a provider of targeted therapies for children and adults with cancer, has raised $130 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination
